Table 2.
Characteristics of renal anemia treatment from the DOPPS among the USA, Europe and Japan (adapted from Karaboyas et al.) [9]
| US DOPPS | Europe DOPPS | Japan DOPPS | |
|---|---|---|---|
| Patients (n) | 8510 | 6757 | 2994 |
| Age (years) (mean ± SD) | 62.4 ± 15.1 | 65.9 ± 14.9 | 64.9 ± 12.0 |
| BMI (kg/m2) (mean ± SD) | 28.7 ± 7.0 | 26.1 ± 5.5 | 21.5 ± 3.5 |
| Hemoglobin (g/dL) (mean ± SD) | 11.2 ± 1.2 | 11.5 ± 1.4 | 10.7 ± 1.2 |
| ESA (×1000 U/week) (mean ± SD) | 15 ± 15 | 10 ± 8 | 6 ± 5 |
| IV iron (%)/dose (mg/week) (mean ± SD) | 77%/75 ± 52 | 79%/74 ± 47 | 33%/32 ± 21 |
| Bolus >500 mg/month in 3–4 months | Bolus 38% | Bolus 22% | Bolus 17% |
| Ferritin (ng/mL) (mean ± SD) | 774 ± 467 | 486 ± 380 | 145 ± 205 |
| CRP (mg/L) | NA | 6 (3–14) | 1 (1–3) |
| Crude all-cause mortality (number of deaths) | 0.146/year (962) | 0.139/year (757) | 0.051/year (137) |
Adapted with permission from NDT. BMI, body mass index; NA, not available.